# Sirolimus in COVID-19 Phase 1

> **NCT04371640** · PHASE1 · WITHDRAWN · sponsor: **Walter K. Kraft**

## Conditions studied

- SARS-CoV-2
- Covid-19

## Interventions

- **DRUG:** Sirolimus 1 MG/ML
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04371640
- **Lead sponsor:** Walter K. Kraft
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07-06
- **Primary completion:** 2021-07-30
- **Final completion:** 2021-07-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study population not regularly admitted to hospital and approaches have shifted away from repurposing old drugs.
- **Last updated:** 2021-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04371640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04371640, "Sirolimus in COVID-19 Phase 1". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04371640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*